Excellent data! Now let me look for biotechs with high analyst upside since I see several pharma/biotech names with massive analyst return potential:
Chinese travel giant Trip.com leads analyst optimism with 966% upside to consensus targets. The $32B hotel platform sits 31% below year-start levels yet analysts see massive recovery potential. Analysts rate the stock a strong buy despite market skepticism.
MU Micron grabbed fresh analyst upgrades this week showing semiconductor confidence. The $363B memory chip maker holds 64% upside to analyst targets despite recent weakness. Multiple firms raised price targets as AI infrastructure demand persisted.
Biotech names dominate extreme analyst optimism rankings. China Yuchai International posted 931% analyst upside as the $1.4B machinery firm trades at deep discounts. Wave Life Sciences holds 300% upside despite plunging 61% year to date. Legend Biotech commands 230% upside potential from analysts.
PH Parker-Hannifin absorbed multiple upgrades today showing industrial momentum. The $112B machinery giant holds 20% analyst upside. GOOGL Alphabet grabbed six new buy ratings despite falling 12% this year with 38% upside potential.
Robinhood Markets shows 80% analyst upside despite tumbling 41% year to date. The $59B fintech holds strong buy consensus as 87 ORTEX stock score signals quality despite volatility.
AppLovin leads software names with 73% upside and 96 stock score. Analysts backed the $125B ad tech firm despite 44% yearly decline showing conviction in recovery potential.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
